Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DGPR1008 PSMA-targeted fluorescent imaging in robot-assisted radical prostatectomy (Phase II)
ChiCTR2500107390Phase 2Not yet recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- Aug 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DGPR1008 in prostate cancer (PCa) (2 arms), sponsored by First Medical Center of Chinese PLA General Hospital. Primary endpoints: Proportion of histopathologically positive tumors in additionally resected NIR-visible tumor bed tissue and Coincidence rate between NIR-fluorescent lymph nodes and histopathologically positive lymph nodes. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
DGPR1008
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500107390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107390.